José Tuñón, Ana Pello, Álvaro Aceña, Sergio Ramos-Cillán, Juan Martínez-Milla, Óscar González-Lorenzo, Jesús Fuentes-Antras, Nieves Tarín, Carmen Cristóbal, Luis M Blanco-Colio, José Luis Martín-Ventura, Ana Huelmos, Carlos Gutiérrez-Landaluce, Marta López-Castillo, Joaquín Alonso, Lorenzo López Bescós, Jesús Egido, Ignacio Mahíllo-Fernández, Óscar Lorenzo
N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels are increased in patients with cancer. In this paper, we test whether NT-proBNP may identify patients who are going to receive a future cancer diagnosis (CD) in the intermediate-term follow-up. We studied 962 patients with stable coronary artery disease and free of cancer and heart failure at baseline. This sample represents a re-analysis of a previous work expanding the sample size and the follow-up. NT-proBNP, galectin-3, monocyte chemoattractant protein-1, high-sensitivity C-reactive protein, high-sensitivity cardiac troponin I (hsTnI), and calcidiol (vitamin D) plasma levels were assessed...
September 7, 2021: Journal of Clinical Medicine